CN103451151B - A kind of method of cultivator umbilical cord mesenchymal stem cells - Google Patents
A kind of method of cultivator umbilical cord mesenchymal stem cells Download PDFInfo
- Publication number
- CN103451151B CN103451151B CN201310243569.6A CN201310243569A CN103451151B CN 103451151 B CN103451151 B CN 103451151B CN 201310243569 A CN201310243569 A CN 201310243569A CN 103451151 B CN103451151 B CN 103451151B
- Authority
- CN
- China
- Prior art keywords
- umbilical cord
- injection
- culturing bottle
- cell
- people
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 129
- 238000000034 method Methods 0.000 title claims abstract description 55
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 33
- 239000007788 liquid Substances 0.000 claims abstract description 46
- 239000007924 injection Substances 0.000 claims abstract description 38
- 238000002347 injection Methods 0.000 claims abstract description 38
- 238000004140 cleaning Methods 0.000 claims abstract description 28
- 229940056360 penicillin g Drugs 0.000 claims abstract description 23
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 claims abstract description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 20
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims abstract description 19
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims abstract description 19
- 229960003942 amphotericin b Drugs 0.000 claims abstract description 19
- 239000000243 solution Substances 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 10
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 238000005304 joining Methods 0.000 claims abstract description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract 8
- 210000004027 cell Anatomy 0.000 claims description 70
- 238000012258 culturing Methods 0.000 claims description 51
- 239000012679 serum free medium Substances 0.000 claims description 21
- 239000008354 sodium chloride injection Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 230000001464 adherent effect Effects 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 235000013372 meat Nutrition 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 210000002249 digestive system Anatomy 0.000 claims description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 4
- 238000009413 insulation Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000002953 phosphate buffered saline Substances 0.000 claims description 4
- 238000013517 stratification Methods 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 abstract description 22
- 238000000926 separation method Methods 0.000 abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 230000024835 cytogamy Effects 0.000 abstract description 2
- 239000012467 final product Substances 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 31
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 230000036512 infertility Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000013190 sterility testing Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000003995 blood forming stem cell Anatomy 0.000 description 3
- 230000003749 cleanliness Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical class OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 101100379068 Caenorhabditis elegans apc-2 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003103 anti-anaerobic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001572 anti-trichomonad Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000004489 deciduous teeth Anatomy 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of method of cultivator umbilical cord mesenchymal stem cells.It comprises the steps: the people's umbilical cord getting fresh collection, cleaning, puts into umbilical cord protection liquid 2-8 DEG C and saves backup; Get the people's umbilical cord being immersed in and being no more than 48 hours in umbilical cord protection liquid; cleaning; put successively again face be respectively the sodium chloride solution of 2500-3500U/mL and 3500-4500U/mL with the benzylpenicillin sodium of newly joining and Vetstrep content and every milliliter embathe containing in the Metronidazule injection of 30-50U Amphotericin B for injection; last cleaning be again placed on carry out in disposable sterilized culture dish for subsequent use; then be separated, be cultured to cytogamy degree and reach 80-90% and get final product.The potential danger that the present invention can avoid the reagent of animal serum and animal-origin to bring; The cultivation of umbilical cord mesenchymal stem cells is all can be used in 48 hours, workable; Can greatly reduce because mould, anerobe pollute the underproof probability of mescenchymal stem cell separation and Culture caused.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of method of cultivator umbilical cord mesenchymal stem cells.
Background technology
Stem cell is a kind of undifferentiated cell, there are two fundamental characteristics, one is have the of self-replication capacity, two is the functioning cells that can be divided into more than one, according to the size of differentiation potential, stem cell is generally divided into three classes, and the first kind is myeloid-lymphoid stem cell (totipotentstemcell), it can be divided into the consistent totipotent cell of function, can grow for fetus; Equations of The Second Kind is pluripotent stem cell (pturipotentstemcel), and it can be divided into often kind of cell type in health, but can not form placenta or the necessary sustentacular tissue of fetation.Because the differentiation potential of pluripotent stem cell is not " entirety ", therefore this cell is not called " all-round ", and they not to be embryos.The further specialization of pluripotent stem cell is multipotency (multiPotent) stem cell, and it is exclusively used in the cell of the specific germline being divided into specific function specialization.Multipotential stem cell can be divided into the cell type contained in the tissue that they are derived from; Such as blood stem cell is merely able to be divided into red blood cell, white cell and thrombocyte.Embryonic stem cell (Embryonicstemcell) has potential widely, can generate except all histocytes of extraplacental body; 3rd class is adult stem cell (aduitstemcell) is the undifferentiated cell that one will have lifelong self-replacation (identicalcopies) and self (self-renewal) ability, it is distributed in different tissues, and can develop and become various types of qualification cell.The classification of stem cell, is mainly divided into hemopoietic stem cell and non-hematopoietic stem cell.Hemopoietic stem cell dominates the disease of blood, immunology, such as Cord blood of originating; Non-hematopoietic stem cell then based on cytodifferentiation and reparation, can be applicable to the regenerative medicines such as apoplexy, diabetes, senile dementia, and there are umbilical cord, placenta, deciduous teeth etc. in source.
Mescenchymal stem cell (mesenchymalstemcellMSC) is the multipotential stem cell that can form various kinds of cell type.Mescenchymal stem cell (MSC) finds in marrow, also finds subsequently to be present in the Various Tissues perhaps of human body generation, growth course.In view of mescenchymal stem cell have multi-lineage potential, can hematopoiesis support and promote that hemopoietic stem cell is implanted, immunity moderation and the feature such as separation and Culture is easy and simple to handle, just day by day receive the concern of people.The range of application of mescenchymal stem cell is also more and more extensive.Carried out multinomial clinical application research both at home and abroad at present, principal disease type comprises osteoarthritis disorders, liver cirrhosis, graft host rejection reaction (GVHD), Spinal injury and degenerative neural disease and diabetes etc.
Summary of the invention
Technical problem to be solved by this invention is a kind of method providing cultivator umbilical cord mesenchymal stem cells.
For solving technical problem of the present invention, the technical solution used in the present invention is as follows:
A method for cultivator umbilical cord mesenchymal stem cells, is characterized in that: it comprises the steps:
(1) people's umbilical cord of fresh collection is got, cleaning, put into umbilical cord protection liquid 2-8 DEG C to save backup, described umbilical cord protection liquid adds benzylpenicillin sodium in AIM-V substratum and Vetstrep obtains, and wherein benzylpenicillin sodium and the final concentration of Vetstrep in umbilical cord protection liquid are respectively 100-200U/mL and 100-200U/mL;
(2) the people's umbilical cord being immersed in and being no more than 48 hours in umbilical cord protection liquid is got, cleaning, put successively again face be respectively the sodium chloride solution of 2500-3500U/mL and 3500-4500U/mL with the benzylpenicillin sodium of newly joining and Vetstrep content and every milliliter embathe containing in the Metronidazule injection of 30-50U amphotericin B, finally again cleaning be placed on carry out in disposable sterilized culture dish for subsequent use;
(3) aseptic cleaned people's umbilical cord is cut into meat gruel shape, adds AIM-V substratum, put in separator tube and be separated with full-automatic separate tissue device, obtain umbilical cord tissue homogenate;
(4) the umbilical cord tissue homogenate that full-automatic separate tissue device is handled well is carried out centrifugal, abandon supernatant, collect lower floor, be placed in culturing bottle, then add serum free medium wherein, be placed in 36-38 DEG C, saturated humidity, volume fraction be the CO of 5%
2cultivate in incubator, to observe bottle wall formed multiple not of uniform size, cell island that cell quantity is intensive time, then obtain human umbilical cord mesenchymal stem cells primary cell mixed solution, then through centrifugal, human umbilical cord mesenchymal stem cells primary cell can be obtained, then reach 80-90% through Secondary Culture to cytogamy degree and get final product.
By such scheme, join again in AIM-V substratum (treatment level) after benzylpenicillin sodium for injection and streptomycin sulphate for injection dissolve by umbilical cord protection liquid in described step (1) in advance and obtain; Benzylpenicillin sodium for injection and streptomycin sulphate for injection are mixed to get by a certain amount of adding in 0.9% sodium chloride injection by the sodium chloride solution that the middle benzylpenicillin sodium of described step (2) and Vetstrep content are respectively 2500-3500U/mL and 3500-4500U/mL; Described every milliliter of preparation of Metronidazule injection containing 30-50U amphotericin B is by Amphotericin B for injection first with after 0.9% sodium chloride injection dissolving, then is mixed to get with the Metronidazule injection of specified quantitative; Described people's umbilical cord benzylpenicillin sodium and Vetstrep content be respectively the sodium chloride solution of 2500-3500U/mL and 3500-4500U/mL and every milliliter be 8-12min containing the time of embathing in the Metronidazule injection of 30-50U amphotericin B.
By such scheme, the cleaning in described step (1) and step (2) is 0.9% sodium chloride injection cleaning.
By such scheme, described step (4) is for after cultivation 5-6 days, take out in not adherent another new culturing bottle of upper stratification, in former culturing bottle and new culturing bottle, all add serum free medium continue to cultivate, and changed liquid once every 3-4 days, human umbilical cord mesenchymal stem cells primary cell can be obtained until cultivation after 10-15 days;
Then the substratum in former culturing bottle and new culturing bottle is shifted out completely, the recombinant animal tryptic phosphate buffered saline buffer submergence attached cell that mass percent is 0.25% is added in former culturing bottle and new culturing bottle, put into 36 ~ 38 DEG C of incubator insulation digestion 7-9 minute, when observing the contracting of attached cell circle, and at the bottom of having departed from bottle after, the serum free medium adding Digestive system equal volume stops digestion, then be transferred in centrifuge tube, centrifugally abandon supernatant, blow the even cell be deposited in bottom centrifuge tube, then according to 4000-6000 cell/cm
2be inoculated in culturing bottle, and supplement serum free medium in culturing bottle, put 36 ~ 38 DEG C, saturated humidity, volume fraction is the CO of 5%
2cultivate in incubator, every 3-4 days full dose changes liquid once, fusion together to attached cell, and degrees of fusion reaches 80-90%, obtains human umbilical cord mesenchymal stem cells, whenever necessary, can repeat aforesaid operations and carry out how increasing for cell cultures.
By such scheme, described T25 culturing bottle can place people's umbilical cord of being no more than 5g through the process of full-automatic separate tissue device, centrifugal after lower-hierarchy cultivate; The described T75 culturing bottle people's umbilical cord that can place 10-15g through the process of full-automatic separate tissue device, centrifugal after lower-hierarchy cultivate; The described T175 culturing bottle people's umbilical cord that can place 30-35g through the process of full-automatic separate tissue device, centrifugal after lower-hierarchy cultivate;
The volume of the serum free medium needed in described T25 culturing bottle is 6-8mL; The volume of the serum free medium needed in described T75 culturing bottle is 20-25mL; The volume of the serum free medium needed in described T175 culturing bottle is 30-35mL.
First the separation preparation of human umbilical cord mesenchymal stem cells requires that umbilical cord tissue has certain activity, is generally the activity ensureing umbilical cord tissue, need to process in time umbilical cord, and this also brings obstacle to practical application.The present invention preserves by the umbilical cord of fresh collection being placed in umbilical cord protection liquid, can reach the effect to microbial disinfection residual in umbilical cord, can maintain again the object of the activity of umbilical cord tissue.The umbilical cord using umbilical cord of the present invention to protect liquid 2-8 DEG C to carry out preserving all can be used for the cultivation of umbilical cord mesenchymal stem cells in 48 hours, and this brings great operability to actual preparation production.
Except this, the present invention is when carrying out aseptic cleaning to umbilical cord, carry out except aseptically process except using the sodium chloride solution of benzylpenicillin sodium and Vetstrep, the present invention is also especially in conjunction with the self-pollution feature of umbilical cord, especially people's umbilical cord that natural labor is collected is subject to the problem of anerobe and mould contamination, with the addition of especially in the Metronidazule injection of Amphotericin B for injection and carry out aseptically process, and the success ratio of human umbilical cord mesenchymal stem cells cultivation can be significantly improved thus.Wherein, Metronidazule injection mainly can be used for the treatment of anti anaerobic bacteria infection, anti-trichomonal, Amphotericin B for injection is polyene antifungal medicine, and it can destroy the eubolism of the fungal cells such as Cryptococcus neoformans, Blastomyces dermatitidis, histoplasma capsulatum, Coccidioides, Sporothrix, Candida thus suppress it to grow.But Amphotericin B for injection has certain toxicity to cell, the present invention, through repeatedly experimental studies have found that, by controlling the concentration of amphotericin B, can reach and make it play a role but the object not affecting the activity of umbilical cord mesenchymal stem cells.
Beneficial effect of the present invention:
(1) the present invention's whole process uses the reagent of serum-free animal origin-free and utilizes full-automatic tissue processor, substitute during traditional human umbilical cord mesenchymal stem cells is cultivated use foetal calf serum, the trypsinase of animal-origin and collagenase, the potential danger that the reagent of animal serum and animal-origin brings can be avoided in clinical application;
(2) put into umbilical cord protection liquid after gathering, the effect keeping in vitro tissue activity can be played, make manufacture have stronger operability, in 48 hours, be separated preparation, still can isolate active good umbilical cord mesenchymal stem cells;
(3) umbilical cord cleaning process is carried out except aseptically process except using the mycillin of wide spectrum, add amphotericin B and Metronidazule injection, to very effective with the umbilical cord process of mould, anerobe in birth process, can greatly reduce because mould, anerobe pollute the underproof probability of mescenchymal stem cell separation and Culture caused.
Embodiment
Embodiment 1
1. ligation after delivery of baby; cut umbilical cord before placenta is given birth to or after giving birth to and be about 10cm; join after 0.9% sodium chloride injection cleaning in umbilical cord protection liquid in 2-8 DEG C of preservation; described umbilical cord protection liquid joins in AIM-V substratum (treatment level) after benzylpenicillin sodium for injection and streptomycin sulphate for injection first being dissolved with a small amount of AIM-V substratum respectively, and wherein benzylpenicillin sodium and the final concentration of Vetstrep in umbilical cord protection liquid are respectively 200U/mL and 200U/mL.So, umbilical cord is put in umbilical cord protection liquid and preserves in 2-8 DEG C of preservation, umbilical cord can be made under the protection of umbilical cord protection liquid all to can be used for separation in 48 hours and prepare mescenchymal stem cell.
2. the aseptic cleaning of people's umbilical cord
From umbilical cord preserving fluid, take out people's umbilical cord with aseptic nipper and put into sterilising vessel, add 250mL0.9% sodium chloride injection, with 8cm aseptic nipper, people's umbilical cord is shaken rinsing once back and forth.After with aseptic nipper, people's umbilical cord is transferred in another sterilising vessel again, add 250mL and face the sodium chloride solution (dense dual anti-solution) being respectively 3200U/mL, 4000U/mL with the benzylpenicillin sodium of newly joining and Vetstrep, shaken back and forth several times by people's umbilical cord with aseptic nipper every 1-2 minute, total immersion washes 10 minutes.With aseptic nipper, people's umbilical cord is picked up again, transfer in sterilising vessel and add every milliliter containing the Metronidazule injection of 50 unit Amphotericin B for injection, embathe 10 minutes in the same way.Embathe rear 8cm aseptic nipper to be picked up by people's umbilical cord, then put in another sterilising vessel, add 0.9% sodium chloride injection, and people's umbilical cord is shaken cleaning three times back and forth, the people's umbilical cord after cleaning is placed in disposable sterilized culture dish.
Above-mentioned dense dual anti-solution is for newly to join before use, and concrete compound method is: get each one of the streptomycin sulphate for injection of the benzylpenicillin sodium for injection of 800,000 units and 1,000,000 units and join in 250mL0.9% sodium chloride injection and obtain.
Above-mentioned every milliliter of preparation containing the Metronidazule injection of 50U amphotericin B: the Amphotericin B for injection one getting 2.5 ten thousand units, adds 5mL0.9% sodium chloride injection and dissolves, and then gets mixing in previous solu 1mL and 100mL Metronidazule injection and obtains.
To finally clean 0.9% sodium chloride injection draw samples of umbilical cord and carry out the detection of microorganism situation through membrane-filter procedure: have no bacterium, mould-growth through 14 days culture sample.
3. the separation preparation of people's umbilical cord stem cells
People's umbilical cord 5cm aseptic nipper aseptically process in disposable sterilized culture dish crossed and scissors remove blood vessel wherein and mucous membrane, are then cut into meat gruel shape by 5cm sterile scissors.Get 10g at every turn and put C pipe (the supporting separator tube of full-automatic tissue processor), add 8mLAIM-V substratum, processing for 2 times as stirred under full-automatic tissue processor (C-01) program through the process of full-automatic separate tissue device, being then transferred in 50mL centrifuge tube; Use the same method the remaining meat gruel shape human umbilical tissue of process, until be all separated all people's umbilical cord tissue.
By people's umbilical cord homogenate centrifugal 15min under 300g that full-automatic tissue processor process obtains, abandon supernatant, collect lower floor, be placed in 2 T25 culturing bottles respectively, then, after adding serum free medium wherein, culturing bottle is put 36 ~ 38 DEG C, saturated humidity, volume fraction be the CO of 5%
2cultivate in incubator.The quantity of culturing bottle can be selected according to the weight of process umbilical cord, people's umbilical cord that the reducible placement of general T25 culturing bottle is no more than 5g through the process of full-automatic separate tissue device, centrifugal after tissue.The substratum that T25 culturing bottle adds is 6-8mL.
4. human umbilical cord mesenchymal stem cells original cuiture
Cultivate after 5 days, get in another culturing bottle of stratification, then in two culturing bottles, all add serum free medium proceed to cultivate, and changed liquid once every 3-4 days, after about 10-15 days, adherent cell growth observed by available inverted microscope, then continue to cultivate, attached cell can be observed and be proliferated into larger cell colony gradually.When observing Tissue Culture Flask wall and forming multiple not of uniform size, cell island that cell quantity is intensive, namely obtain human umbilical cord mesenchymal stem cells primary cell mixed solution, then through centrifugal, human umbilical cord mesenchymal stem cells primary cell can be obtained.
5. human umbilical cord mesenchymal stem cells goes down to posterity
Substratum in culturing bottle is shifted out completely, add in culturing bottle mass percent be 0.25% the tryptic phosphate buffered saline buffer of recombinant animal (T25 adds 3mL, T75 adds 4mL, T175 adds 6mL), then put into 36 ~ 38 DEG C of incubator insulations and digest about 7-9 minute, the contracting of attached cell circle is observed in the process under inverted microscope, and cell to have departed from bottle at the bottom of after, the serum free medium adding Digestive system equal volume stops digestion, then be transferred in centrifuge tube, count cytoactive with on binocular microscope with tally counting and trypan blu e dyeing thereof.Then centrifuge tube is put centrifugal 5min under 300g condition, after centrifugal, abandon supernatant, blow the even cell be deposited in bottom centrifuge tube gently with Pasteur's pipe, then according to 4000-6000 cell count/cm
2be inoculated in culturing bottle, and carry out mark, in culturing bottle, supplement serum free medium, put 36 ~ 38 DEG C, saturated humidity, volume fraction is the CO of 5%
2cultivate in incubator, every 3-4 days full dose changes liquid once.When after cultivation 24h, passage cell starts adherent, becomes single dispersion long strip shape cell, changes liquid can remove non-attached cell after 3-4 days by full dose, and now cell is the spindle shape cell that degrees of fusion reaches about 50%.After about 6 days, cell based instinct reaches the fusion of more than 80%, mescenchymal stem cell, then can repeat aforesaid operations as required and carry out P2, P3, P4 ... go down to posterity.
Embodiment 2
1. ligation after delivery of baby; cut umbilical cord before placenta is given birth to or after giving birth to and be about 10cm; join after 0.9% sodium chloride injection cleaning in umbilical cord protection liquid in 2-8 DEG C of preservation; described umbilical cord protection liquid is add benzylpenicillin sodium and Vetstrep in AIM-V substratum (treatment level), and wherein benzylpenicillin sodium and the final concentration of Vetstrep in umbilical cord protection liquid are respectively 100U/mL and 100U/mL.So, umbilical cord is put in umbilical cord protection liquid and preserves in 2-8 DEG C of preservation, umbilical cord can be made under the protection of umbilical cord protection liquid all to can be used for separation in 48 hours and prepare mescenchymal stem cell.
2. the aseptic cleaning of people's umbilical cord
From umbilical cord preserving fluid, take out people's umbilical cord with aseptic nipper and put into sterilising vessel, add 0.9% sodium chloride injection, with 8cm aseptic nipper, people's umbilical cord is shaken rinsing once back and forth.After with aseptic nipper, people's umbilical cord is transferred in another sterilising vessel again, add the sodium chloride solution (dense dual anti-solution) facing and be respectively 2500U/mL, 3500U/mL with the benzylpenicillin sodium of newly joining and Vetstrep, shaken back and forth several times by people's umbilical cord with aseptic nipper every 1-2 minute, total immersion washes 8 minutes.With aseptic nipper, people's umbilical cord is picked up again, transfer in sterilising vessel and add every milliliter containing the Metronidazule injection of 30U amphotericin B, embathe 8 minutes in the same way.Embathe rear 8cm aseptic nipper to be picked up by people's umbilical cord, then put in another sterilising vessel, add 0.9% sodium chloride injection, and people's umbilical cord is shaken cleaning three times back and forth, the people's umbilical cord after cleaning is placed in disposable sterilized culture dish.
Above-mentioned dense dual anti-solution is for newly to join before use, and it is preparation and every milliliter of compound method reference example 1 containing the Metronidazule injection of 30U Amphotericin B for injection specifically.
To finally clean 0.9% sodium chloride injection draw samples of umbilical cord and carry out the detection of microorganism situation through membrane-filter procedure: have no bacterium, mould-growth through 14 days culture sample.
3. the separation preparation of people's umbilical cord stem cells
People's umbilical cord 5cm aseptic nipper aseptically process in disposable sterilized culture dish crossed and scissors remove blood vessel wherein and mucous membrane, are then cut into meat gruel shape by 5cm sterile scissors.Get 10g at every turn and put C pipe (the supporting separator tube of full-automatic tissue processor), add 8mLAIM-V substratum, through the process of full-automatic separate tissue device, be then transferred in 50mL centrifuge tube; Use the same method the remaining meat gruel shape human umbilical tissue of process, until be all separated all people's umbilical cord tissue.
By people's umbilical cord homogenate centrifugal 15min under 300g that full-automatic tissue processor process obtains, abandon supernatant, collect lower floor, be placed in culturing bottle, then, after adding serum free medium wherein, culturing bottle is put 36 ~ 38 DEG C, saturated humidity, volume fraction be the CO of 5%
2cultivate in incubator.
4. human umbilical cord mesenchymal stem cells original cuiture
Cultivate after 5 days, get in another culturing bottle of stratification, then in two culturing bottles, all add serum free medium proceed to cultivate, and changed liquid once every 3-4 days, after about 10-15 days, adherent cell growth observed by available inverted microscope, then continue to cultivate, attached cell can be observed and be proliferated into larger cell colony gradually.When observing Tissue Culture Flask wall and forming multiple not of uniform size, cell island that cell quantity is intensive, namely obtain human umbilical cord mesenchymal stem cells primary cell mixed solution, then through centrifugal, human umbilical cord mesenchymal stem cells primary cell can be obtained.
5. human umbilical cord mesenchymal stem cells goes down to posterity
Substratum in culturing bottle is shifted out completely, the tryptic phosphate buffered saline buffer of recombinant animal that mass percent is 0.25% is added in culturing bottle, then put into 36 ~ 38 DEG C of incubator insulations and digest about 7-9 minute, the contracting of attached cell circle is observed in the process under inverted microscope, and cell to have departed from bottle at the bottom of after, the serum free medium adding Digestive system equal volume stops digestion, then be transferred in centrifuge tube, count cytoactive with on binocular microscope with tally counting and trypan blu e dyeing.Then centrifuge tube is put centrifugal 5min under 300g condition, after centrifugal, abandon supernatant, blow the even cell be deposited in bottom centrifuge tube gently with Pasteur's pipe, then according to 4000-6000 cell count/cm
2be inoculated in culturing bottle, and carry out mark, supplement serum free medium in culturing bottle, put 36 ~ 38 DEG C, saturated humidity, volume fraction is the CO of 5%
2cultivate in incubator, every 3-4 days full dose changes liquid once.When after cultivation 24h, passage cell starts adherent, becomes single dispersion long strip shape cell, changes liquid can remove non-attached cell after 3-4 days by full dose, and now cell is the spindle shape cell that degrees of fusion reaches about 50%.After about 6 days, cell based instinct reaches the fusion of more than 80%, mescenchymal stem cell, then can repeat aforesaid operations as required and carry out P2, P3, P4 ... go down to posterity.
The mescenchymal stem cell that embodiment 1 and 2 obtains is carried out FCM analysis, detection method and the results are shown in down:
Experimental principle: utilize Flow Cytometry to detect fluorescent-labeled antibody.According to antigen-antibody combination principle, with the antibody of specific fluorescent element mark, the known cell carrying corresponding antigens is dyeed.Cell through fluorescein labelled antibody dyeing can by flow cytometer identification, and the intensity of fluorescein entrained by known cell, carry out qualitative to traget antibody, quantitative analysis.
Detecting step:
(1) get 5 streaming pipes, be labeled as control tube 1. FITC/PE/APC 2. FITC/PE sample tube 3. 90/34/14 4. DR/105/19 5. 45/34 respectively.
(2) each streaming pipe adds passage cell (number of nucleated cells 2-5 × 10 of identical amount respectively
5individual), can not tube wall be adhered to.
(3) 1. control tube adds MouseIgG2a-PE, MouseIgG1-FITC, MouseIgG1-APC 5ul respectively, mixing; 2. control tube adds MouseIgG2a-PE, MouseIgG1-FITC 5ul respectively, mixing; 3. sample tube adds CD90-FITC, CD73-PE, CD14-APC 5ul respectively, mixing; 4. sample tube adds DR-FITC, CD105-PE, CD19-APC 5ul respectively, mixing; 5. sample tube adds CD45-FITC, CD34-PE 5ul respectively, mixing.
(4) room temperature lucifuge places 15min, adds 2mLPBS/ pipe, 1400rpm/min, centrifugal 5min.
(5) supernatant, upsprings pipe inner cell, adds 0.5mLPBS, mixing, upper machine testing (if can not go up machine in time, should add paraformaldehyde and fix).
(6) upper machine analytical results is as follows: CD73, CD90, CD105 are greater than 95%, are the positive; CD14, CD19, CD34, CD4,5HLA-DR are less than 2%, are feminine gender.
Above-mentioned explanation: the human umbilical cord mesenchymal stem cells obtained according to the method separation and Culture in embodiment, meets CD73, CD90, CD105 and be greater than 95% is the positive; CD14, CD19, CD34, CD4,5HLA-DR are less than 2%, are the result of feminine gender, through being accredited as mescenchymal stem cell.
The membrane-filter procedure used in above-mentioned Sterility testing process is as follows:
Sterility Test comprises than membrane-filter procedure and direct inoculation, and membrane-filter procedure can avoid effectively removing microbiotic and other water-soluble substanceses to the interference of Sterility testing, can reflect the state that in cell cultivation process, microorganism exists more accurately.
The Sterility testing of the present embodiment is adopted and is detected according to " Chinese Pharmacopoeia 2010 editions " membrane-filter procedure, adopts HTY-601 germ collector and APY serial culture device.The whole process of Sterility testing all under environment cleanliness 10000 grades local cleanliness factor 100 grades way flow air section in carry out, its whole process strictly observes aseptic technique, prevents microbial contamination.The cleanliness factor of isolated system internal medium meets the requirement of sterility test.
Concrete implementation step is as follows:
(1) take out incubator and first check whether packaging stands intact.Inspection filter sizes should be not more than 0.45 μm, and diameter is about 50mm.Filter membrane material is selected according to trial-product characteristic, should through suitable method sterilizing before filter and filter membrane use.During use, the integrity after filter membrane before filtration should be ensured.
(2) inserted one by one in stainless steel seat by incubator, the elastic hose of incubator is loaded germ collector pump head, note accurate positioning, flexible pipe tendency is smooth and easy.
(3) wetting filter membrane: select the sodium-chlor-peptone buffer agent of PH7.0 as washing fluid, washes geramine with 75% ethanol or 0.2% and carefully carries out disinfection at (position of particularly container top needs puncture) to the cleaning liquid bottle surface of band plug, dry.Then supravasal for incubator syringe needle is inserted in washing fluid container plug, open germ collector, adjusting rotary speed is 160RMP, being inverted cleaning liquid bottle after starting about 3 seconds and being placed in carries on bottle stand, about 50ml washing fluid is injected in every cup, wetting filter membrane (wetting liquid is without the need to being filtered dry), takes off cleaning liquid bottle and stands in operating table surface, stop germ collector after evacuation of liquid.
(4) dilution of trial-product, transfer, filtration: wash geramine with 75% ethanol or 0.2% and carefully sample hose dress trial-product surface is carried out disinfection, dry.Open the lid of sample hose, sample pipe shaft is held with 45 DEG C of angles, then supravasal for incubator syringe needle is inserted to the bottom of sample hose, open germ collector, adjusting rotary speed is 160RMP, to be transferred to by test liquid in cup and to filter, treat test liquid discharge to the greatest extent, stop germ collector.
(5) rinse: the elasticity helmet taking off cup filter bowl upper port.Inserted by syringe needle in cleaning liquid bottle, open germ collector, adjusting rotary speed is 160RMP, then is inverted by cleaning liquid bottle, injects about about 100mL washing fluid, rinse 3 times in every cup.Take off red helmet pressure release after flushing completes, use yellow cap stopper to close liquid outlet (rotation push-tight), then substratum is reentered in sump pit.Pay special attention to: when rinsing, not advising carrying out excessive jolting to cup, otherwise causing washing fluid to enter air filter.
(6) substratum is added:
An other pipe of incubator four-way and location buckle is clamped with red intermediate plate.Start germ collector with 100R rotating speed, then be inverted medium bottle, make all THIOGLYCOLLIC ACID salt fluid media transfer in incubator cup.First clamp another two pipes with green intermediate plate, more red intermediate plate is taken away, inject improvement Martin substratum, equipment operation is with adding THIOGLYCOLLIC ACID salt broth.When two cups fill it up with substratum entirely, clamp the flexible pipe from 2 ~ 3cm place above incubator cup with corresponding intermediate plate, cut two flexible pipes simultaneously, leave 5 ~ 6cm, and other end is inserted the air filter place of cup.(scissors needed spirit lamp flame)
(7) get corresponding washing fluid to operate with method, as negative control.
(8) colony culture device containing substratum of end of operation is shifted out sterilisable chamber, get one pipe and make positive control, add corresponding contrast bacterium liquid according to Positive contrast bacteria selection principle.
(9) THIOGLYCOLLIC ACID salt broth is cultivated 14 days at 30 ~ 35 DEG C, and improvement Martin substratum is cultivated 14 days at 23 ~ 28 DEG C.Day by day should check whether bacteria growing between incubation period, and fill in sterility test record.As muddy or precipitation appears in trial-product pipe, when can not judge from outward appearance after cultivating, this nutrient solution desirable is seeded in another identical fresh culture, microbial culture 2 days, fungus culture 3 days, and whether the fresh culture of the same race observing inoculation occurs muddiness again; Or get nutrient solution smear, dyeing, microscopy, has judged whether bacterium.
(10) result judges: well-grown answered by positive control pipe, and negative control pipe must not have bacteria growing.Otherwise, invalidate the test.
If trial-product pipe is all clarified, though or aobvious muddy through confirmation asepsis growth, sentence trial-product and conform with the regulations; If any aobvious muddiness is also confirmed in trial-product pipe bacteria growing, sentence trial-product against regulation, unless energy sufficient proof experimental result is invalid, contained by the non-trial-product of the microorganism namely grown.When meeting at least one condition following, can test-results be sentenced invalid:
1. the microorganism monitored results of sterility test test equipment used and environment does not meet sterility test requirement;
2. look back sterility test process, find that there is the factor that may cause microbial contamination;
2. the microorganism grown in trial-product pipe is after qualification, and confirmation is article because using in sterility test and (or) aseptic technique is improper causes.If it is invalid through confirming to test, answer retry.During retry, again getting with measuring trial-product, checking in accordance with the law, if asepsis growth, sentencing trial-product and conform with the regulations; If there is bacteria growing, sentence trial-product against regulation.
Claims (4)
1. a method for cultivator umbilical cord mesenchymal stem cells, is characterized in that: it comprises the steps:
(1) people's umbilical cord of fresh collection is got, cleaning, put into umbilical cord protection liquid 2-8 DEG C to save backup, described umbilical cord protection liquid adds benzylpenicillin sodium in AIM-V substratum and Vetstrep obtains, and wherein benzylpenicillin sodium and the final concentration of Vetstrep in umbilical cord protection liquid are respectively 100-200U/mL and 100-200U/mL;
(2) the people's umbilical cord being immersed in and being no more than 48 hours in umbilical cord protection liquid is got, cleaning, put successively again face be respectively the sodium chloride solution of 2500-3500U/mL and 3500-4500U/mL with the benzylpenicillin sodium of newly joining and Vetstrep content and every milliliter embathe containing in the Metronidazule injection of 30-50U amphotericin B, finally again cleaning be placed on carry out in disposable sterilized culture dish for subsequent use;
(3) aseptic cleaned people's umbilical cord is cut into meat gruel shape, adds AIM-V substratum, put in separator tube and be separated with full-automatic separate tissue device, obtain umbilical cord tissue homogenate;
(4) the umbilical cord tissue homogenate that full-automatic separate tissue device is handled well is carried out centrifugal, abandon supernatant, collect lower floor, be placed in culturing bottle, cultivate after 5-6 days, take out in not adherent another new culturing bottle of upper stratification, in former culturing bottle and new culturing bottle, all add serum free medium continue to cultivate, and changed liquid once every 3-4 days, after cultivation 10-15 days, to observe bottle wall is formed multiple not of uniform size, during the intensive cell island of cell quantity, then obtain human umbilical cord mesenchymal stem cells primary cell mixed solution, then through centrifugal, human umbilical cord mesenchymal stem cells primary cell can be obtained, then the substratum in former culturing bottle and new culturing bottle is shifted out completely, the recombinant animal tryptic phosphate buffered saline buffer submergence attached cell that mass percent is 0.25% is added in former culturing bottle and new culturing bottle, put into 36 ~ 38 DEG C of incubator insulation digestion 7-9 minute, when observing the contracting of attached cell circle, and at the bottom of having departed from bottle after, the serum free medium adding Digestive system equal volume stops digestion, then be transferred in centrifuge tube, centrifugally abandon supernatant, blow the even cell be deposited in bottom centrifuge tube, again according to 4000-6000 cell/cm
2be inoculated in culturing bottle, and supplement serum free medium in culturing bottle, put 36 ~ 38 DEG C, saturated humidity, volume fraction is the CO of 5%
2cultivate in incubator, every 3-4 days full dose changes liquid once, fusion together to attached cell, and degrees of fusion reaches 80-90%, obtains human umbilical cord mesenchymal stem cells, whenever necessary, can repeat aforesaid operations and carry out how increasing for cell cultures.
2. the method for cultivator umbilical cord mesenchymal stem cells according to claim 1, is characterized in that: join in treatment level AIM-V substratum after benzylpenicillin sodium for injection and streptomycin sulphate for injection dissolve by umbilical cord protection liquid in described step (1) in advance again and obtain; Benzylpenicillin sodium for injection and streptomycin sulphate for injection are mixed to get by a certain amount of adding in 0.9% sodium chloride injection by the sodium chloride solution that the middle benzylpenicillin sodium of described step (2) and Vetstrep content are respectively 2500-3500U/mL and 3500-4500U/mL; Described every milliliter of preparation of Metronidazule injection containing 30-50U amphotericin B is by Amphotericin B for injection first with after 0.9% sodium chloride injection dissolving, then is mixed to get with the Metronidazule injection of specified quantitative; Described people's umbilical cord benzylpenicillin sodium and Vetstrep content be respectively the sodium chloride solution of 2500-3500U/mL and 3500-4500U/mL and every milliliter be 8-12min containing the time of embathing in the Metronidazule injection of 30-50U amphotericin B.
3. the method for cultivator umbilical cord mesenchymal stem cells according to claim 1, is characterized in that: the cleaning in described step (1) and step (2) is 0.9% sodium chloride injection cleaning.
4. the method for cultivator umbilical cord mesenchymal stem cells according to claim 1, is characterized in that: T25 culturing bottle can place people's umbilical cord of being no more than 5g through the process of full-automatic separate tissue device, centrifugal after lower-hierarchy cultivate; The T75 culturing bottle people's umbilical cord that can place 10-15g through the process of full-automatic separate tissue device, centrifugal after lower-hierarchy cultivate; The T175 culturing bottle people's umbilical cord that can place 30-35g through the process of full-automatic separate tissue device, centrifugal after lower-hierarchy cultivate; The volume of the serum free medium needed in T25 culturing bottle is 6-8mL; The volume of the serum free medium needed in T75 culturing bottle is 20-25mL; The volume of the serum free medium needed in T175 culturing bottle is 30-35mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310243569.6A CN103451151B (en) | 2013-06-19 | 2013-06-19 | A kind of method of cultivator umbilical cord mesenchymal stem cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310243569.6A CN103451151B (en) | 2013-06-19 | 2013-06-19 | A kind of method of cultivator umbilical cord mesenchymal stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103451151A CN103451151A (en) | 2013-12-18 |
| CN103451151B true CN103451151B (en) | 2016-01-20 |
Family
ID=49733993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310243569.6A Active CN103451151B (en) | 2013-06-19 | 2013-06-19 | A kind of method of cultivator umbilical cord mesenchymal stem cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103451151B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104232572A (en) * | 2014-08-20 | 2014-12-24 | 北京瑞思德生物科技有限公司 | Kit for preparing umbilical cord mesenchymal stem cells |
| CN104705289B (en) * | 2015-03-01 | 2016-08-24 | 安徽新生命干细胞科技有限公司 | A kind of teeth in vitro preserves liquid |
| CN104673748A (en) * | 2015-03-19 | 2015-06-03 | 河南中科干细胞基因工程有限公司 | Method for extracting mesenchymal stem cells from human umbilical cord |
| CN104762256A (en) * | 2015-03-26 | 2015-07-08 | 湖北省生命源干细胞有限公司 | Method for extracting mesenchymal stem cells from umbilical cord Wharton's jelly |
| CN104983742A (en) * | 2015-04-22 | 2015-10-21 | 南京康雅生物科技有限公司 | Stem cell preparation for treating degenerative osteoarthropathy and preparation method of stem cell preparation |
| CN106190810A (en) * | 2016-08-30 | 2016-12-07 | 浙江泰林生物技术股份有限公司 | A kind of membrane filtration sterility test device |
| CN106719601A (en) * | 2016-11-30 | 2017-05-31 | 广州赛莱拉干细胞科技股份有限公司 | A kind of umbilical cord preserving fluid and its application |
| CN112159795A (en) * | 2020-10-13 | 2021-01-01 | 肖利霞 | Passage amplification method for umbilical cord mesenchymal stem cell working cells in public bank |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1878860A (en) * | 2003-11-11 | 2006-12-13 | 韩薰 | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood |
| CN101575590A (en) * | 2005-02-28 | 2009-11-11 | 中国医学科学院血液学研究所泰达生命科学技术研究中心 | Method for preparing human umbilical cord mesenchymal stem cells |
| CN101922048A (en) * | 2010-08-06 | 2010-12-22 | 青岛奥克生物开发有限公司 | Method for constructing public library of umbilical mesenchymal stem cells |
| CN101974484A (en) * | 2010-11-03 | 2011-02-16 | 江苏省北科生物科技有限公司 | Method for preparing human umbilical cord mesenchymal stem cells |
| CN102117522A (en) * | 2011-01-14 | 2011-07-06 | 张伟 | Online shopping terminal |
-
2013
- 2013-06-19 CN CN201310243569.6A patent/CN103451151B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1878860A (en) * | 2003-11-11 | 2006-12-13 | 韩薰 | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood |
| CN101575590A (en) * | 2005-02-28 | 2009-11-11 | 中国医学科学院血液学研究所泰达生命科学技术研究中心 | Method for preparing human umbilical cord mesenchymal stem cells |
| CN101922048A (en) * | 2010-08-06 | 2010-12-22 | 青岛奥克生物开发有限公司 | Method for constructing public library of umbilical mesenchymal stem cells |
| CN101974484A (en) * | 2010-11-03 | 2011-02-16 | 江苏省北科生物科技有限公司 | Method for preparing human umbilical cord mesenchymal stem cells |
| CN102117522A (en) * | 2011-01-14 | 2011-07-06 | 张伟 | Online shopping terminal |
Non-Patent Citations (2)
| Title |
|---|
| 人脐带间充质干细胞治疗神经系统疾病的研究进展;范存刚等;《国际神经病学神经外科学杂志》;20090331;第36卷(第3期);242-244 * |
| 无血清培养基分离培养脐带间充质干细胞的研究;方彦艳等;《同济大学学报》;20101031;第31卷(第5期);22 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103451151A (en) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103451151B (en) | A kind of method of cultivator umbilical cord mesenchymal stem cells | |
| CN105713871A (en) | Human chorion mesenchymal stem cell isolated culture method | |
| WO2004011593A1 (en) | Automatic culture apparatus for cell or tisse with biological origin | |
| CN110157666A (en) | Umbilical cord mesenchymal stem cells MSCs and its cultural method and application | |
| CN106367389A (en) | Preparation method and application of human umbilical cord mesenchymal stem cell factors | |
| CN104152409B (en) | Method for simultaneous isolated culture of canine bone marrow mesenchymal stem cells and multifunctional hematopoietic stem cells | |
| CN101591644A (en) | Preparation and storage of umbilical cord mesenchymal stem cells for clinical treatment | |
| CN110623917A (en) | Beautifying and skin repairing sodium hyaluronate gel coated with stem cell complex factor | |
| CN101693884B (en) | Method for separating and extracting stem cells from placenta, umbilical cord or adipose tissue | |
| CN107177546A (en) | A kind of preparation method of type I collagen culture medium and type I collagen | |
| CN103756965B (en) | A kind of method of lavation hemopoietic stem cell from placenta | |
| CN104622709B (en) | Human stem cell factor skin repair liquid and preparation method thereof | |
| CN103555663B (en) | Method for cultivating human amniotic mesenchymal stem cells | |
| CN107022525A (en) | NK cell culture processes for oncotherapy | |
| CN102936612A (en) | Method for preparing anti-canine distemper virus monoclonal antibody by adopting bioreactor | |
| CN108949682A (en) | A kind of preparation, culture and the purification process of dental pulp mescenchymal stem cell | |
| WO2019245050A1 (en) | Hollow fiber cell culture device, cell culture method, and method for producing culture supernatant | |
| CN108642002A (en) | A kind of method of serum-free domestication culture human mesenchymal stem cell | |
| CN107502588A (en) | A kind of method that separation prepares dental pulp stem cell | |
| CN103555664B (en) | A kind of method of cultivator placenta mesenchyma stem cell | |
| CN204039387U (en) | A kind of acquisition process test kit for obtaining stem cell in tooth | |
| CN101161249B (en) | Method for extracting original mesenchyma and hematopoiesis trunks/ancestral cell from caesarean birth placenta | |
| CN104388391B (en) | Mice paneth's cell hybridoma cell strain, preparation method and applications | |
| CN108066824A (en) | A kind of new method for preparing skin blemish medicine | |
| WO2012122603A1 (en) | Cell processing method and device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |